Ronapreve Monoclonal Antibodies Approved In Malaysia!

Ronapreve Monoclonal Antibodies Approved In Malaysia!

The Ronapreve monoclonal antibodies from Regeneron have just been approved in Malaysia!

Here is what you need to know…

 

Ronapreve Monoclonal Antibodies Approved In Malaysia!

On 14 December 2021, the Malaysia Drug Control Authority (DCA) agreed to give conditional approval for the use of Ronapreve monoclonal antibodies to treat or prevent COVID-19.

Name : Ronapreve Solution for Injection or Infusion
Registration Holder : Roche (Malaysia) Sdn. Bhd.

Manufacturer : F.Hoffman-La Roche Ltd, Switzerland

Treatment

Ronapreve is indicated for the treatment of COVID-19 in adults and adolescents aged 12 years and older and weighing at least 40 kg who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID‑19.

Prevention

Ronapreve is indicated for the prevention of COVID-19 in adults and adolescents aged 12 years and older and weighing at least 40 kg who have been exposed or at high risk of exposure to SARS-CoV-2 and who either,

  • have a medical condition making them unlikely to respond to or be protected by vaccination, or
  • are not vaccinated against COVID-19.

 

Ronapreve Monoclonal Antibodies : A Quick Primer!

Developed by Regeneron Pharmaceuticals, Ronapreve (also known as REGEN-COV) is a cocktail of two human monoclonal antibodies – casirivimab and imdevimab.

These monoclonal antibodies are essentially lab-manufactured versions of the antibodies that our own immune system creates after we are vaccinated against COVID-19.

Just like antibodies created by most COVID-19 vaccines, both casirivimab and imdevimab target the SARS-CoV-2 spike protein, binding with it to prevent the virus from attaching to our cells.

Hence, it is used early in a COVID-19 infection, preferably right after exposure, especially in unvaccinated or immunocompromised people.

Ronapreve is not a replacement for COVID-19 vaccines, because it only offers temporary protection through artificial antibodies, whereas vaccination teaches our own immune system to create its own antibodies for lasting protection.

Ronapreve is also extremely expensive, reportedly costing 310,000 yen (~RM11,500) in Japan and ₹57,750 (~RM3,200) in India. I have no idea how much it will cost in Malaysia, but it is certainly going to fall between those two extremes!

So, don’t think of relying on Ronapreve. Get vaccinated against COVID-19. Your wallet will thank you!

 

Please Support My Work!

Support my work through a bank transfer /  PayPal / credit card!

Name : Adrian Wong
Bank Transfer : CIMB 7064555917 (Swift Code : CIBBMYKL)
Credit Card / Paypal : https://paypal.me/techarp

Dr. Adrian Wong has been writing about tech and science since 1997, even publishing a book with Prentice Hall called Breaking Through The BIOS Barrier (ISBN 978-0131455368) while in medical school.

He continues to devote countless hours every day writing about tech, medicine and science, in his pursuit of facts in a post-truth world.

 

Recommended Reading

Go Back To > Healthcare | Tech ARP

 

Support Tech ARP!

Please support us by visiting our sponsors, participating in the Tech ARP Forums, or donating to our fund. Thank you!

Leave a Reply Cancel reply